Research
Hormonal
Tirzepatide demonstrates superior efficacy compared to Semaglutide in reducing HbA1c levels, but shows no clear superiority in weight loss or FBS reduction.
If your current Semaglutide treatment is not lowering your HbA1c enough, switching to Tirzepatide may provide better blood sugar control. However, do not expect significantly more weight loss from this switch, as both drugs appear to offer similar weight reduction benefits in this analysis.
ModerateQualifiesMEDIUM confidence
Tirzepatide exhibited a notable advantage over Semaglutide in reducing HbA1c levels (−0.45; 95% CI: −0.88 to −0.02; p = 0.04). However, no clear superiority was observed for weight and FBS change.
Why this rating
Based on only 2 RCTs.
Source
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
Mohammad Amin Karimi et al. · Frontiers in Pharmacology · 2025
DOI 10.3389/fphar.2025.1438318
Meta-analysis · 16 studiesCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide demonstrates superior efficacy compared to Liraglutide in reducing hemoglobin A1c (HbA1c) levels, though it shows no significant difference in weight loss or fasting blood sugar (FBS) reduction compared to Liraglutide.Good
- Semaglutide demonstrates superior efficacy compared to Dulaglutide in reducing both HbA1c and Fasting Blood Sugar (FBS), but shows no significant difference in weight loss or BMI reduction.Good
- Switching from Liraglutide to Semaglutide results in significant additional weight loss and FBS reduction, but does not significantly impact HbA1c levels.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →